Retatrutide Shows 28% Weight Loss in Phase 3 Trial - Top_Thought_Leaders - MDSpire

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

  • By

  • Kathryn Wighton

  • May 21, 2026

  • 2 min

Share

Top Thought Leaders in Pathology

Brief introduction explaining scope and methodology.

Original Source(s)

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

  • by Kathryn Wighton

  • May 21, 2026

Related Content

Analytical Champions: Tao Chen

A new series championing analytical scientists in pharma begins with Genentech’s rising star

  • May 22, 2026

  • 8 min
High-Resolution Spectroscopy on a Silicon Chip

A photonic–computational spectrometer smaller than 0.002 mm² delivers picometer-scale spectral resolution 

  • May 21, 2026

  • 2 min
Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.